We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amarin (AMRN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of our Medical group, which includes 891 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AMRN's full-year earnings has moved 12.1% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AMRN has moved about 3.9% on a year-to-date basis. In comparison, Medical companies have returned an average of -6.6%. This shows that Amarin is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is BioAge Labs, Inc. (BIOA - Free Report) . The stock has returned 38.8% year-to-date.
For BioAge Labs, Inc., the consensus EPS estimate for the current year has increased 8.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #143 in the Zacks Industry Rank. On average, stocks in this group have gained 1.3% this year, meaning that AMRN is performing better in terms of year-to-date returns. BioAge Labs, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Amarin and BioAge Labs, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amarin (AMRN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of our Medical group, which includes 891 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AMRN's full-year earnings has moved 12.1% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AMRN has moved about 3.9% on a year-to-date basis. In comparison, Medical companies have returned an average of -6.6%. This shows that Amarin is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is BioAge Labs, Inc. (BIOA - Free Report) . The stock has returned 38.8% year-to-date.
For BioAge Labs, Inc., the consensus EPS estimate for the current year has increased 8.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #143 in the Zacks Industry Rank. On average, stocks in this group have gained 1.3% this year, meaning that AMRN is performing better in terms of year-to-date returns. BioAge Labs, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Amarin and BioAge Labs, Inc. as they attempt to continue their solid performance.